Our study clearly indicates the contribution of NO from LECs to inhibition of LSMC function in the setting of TNF overexpression, which provides experimental evidence for the use of NOS inhibitors in the treatment of RA. This evidence concerns the gene NOS2 and rheumatoid arthritis.